The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / November / A New Role for Lateral Flow in Cancer Diagnosis
Oncology Point of care testing Molecular Pathology

A New Role for Lateral Flow in Cancer Diagnosis

A quantitative colorimetric assay distinguished patients with PDAC from healthy controls

11/19/2026 News 2 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll

Share

5 Key Takeaways
  • 1

    Researchers developed a quantitative colorimetric lateral flow immunoassay to measure soluble AXL (sAXL) in plasma as a potential aid to pancreatic ductal adenocarcinoma diagnosis.

  • 2

    The assay uses capture and biotinylated detection antibodies, with anti-biotin gold nanoparticles generating a visible signal.

  • 3

    In a cohort of 20 patients with pancreatic ductal adenocarcinoma and 20 healthy controls, the assay detected higher sAXL concentrations and statistically differentiated the groups.

  • 4

    The study was an early clinical evaluation and did not assess whether the assay distinguishes pancreatic cancer from chronic pancreatitis or other relevant diseases.

  • 5

    The findings do not establish the assay for screening or as a replacement for imaging, histopathology, cytology, or laboratory ELISA; larger independent studies are needed.

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.